Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Eur Rev Med Pharmacol Sci ; 25(24): 7985-7996, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34982462

RESUMO

OBJECTIVE: This study aimed to improve the post-marketing surveillance on mRNA anti-SARS-CoV-2 vaccines, characterizing the adverse events (AEs) after the first dose of mRNA BNT162b vaccine. The associations between the AEs and individuals' characteristics were explored. PATIENTS AND METHODS: All adult healthcare workers at Niguarda Hospital (Milan, Italy) who were referred for the first dose of vaccine were offered to participate in a cross-sectional survey during the second-dose administration, between 18 January and 7 February 2021. All participants completed a questionnaire about age, gender, weight, height, medical history, concurrent therapies, employment status, previous diagnosis/testing for SARS-CoV-2 infection, and a list of 24 AEs (solicited AEs). The development of at least one solicited AEs was the main outcome. AEs were stratified by the presence of injection-site symptoms, systemic symptoms or both, and the differences between strata were assessed as a secondary outcome. Biometric data and reports of a previous diagnosis of SARS-CoV-2 infection were also explored, as predictors of the main outcome. RESULTS: 7,014 healthcare workers were included. An incidence of 3 per 10.000 persons for serious AEs following the first administration of the mRNA BNT162b vaccine was found. An association between the development of non-serious AEs with young age, female gender, low body mass index, and previous history of SARS-CoV-2 was described. CONCLUSIONS: This real-life study supported data on the safety profile of the BNT162b2 mRNA vaccine. Our findings on the associations between the development of non-serious AEs with some individual characteristics may help physicians and patients make educated and informed medical decisions towards anti-COVID-19 vaccination.


Assuntos
Vacina BNT162/efeitos adversos , COVID-19/prevenção & controle , Vacinação/efeitos adversos , Adulto , Fatores Etários , Vacina BNT162/administração & dosagem , COVID-19/epidemiologia , COVID-19/imunologia , COVID-19/virologia , Estudos Transversais , Feminino , Pessoal de Saúde/estatística & dados numéricos , Humanos , Masculino , Anamnese/estatística & dados numéricos , Pessoa de Meia-Idade , Vigilância de Produtos Comercializados/estatística & dados numéricos , Fatores de Risco , SARS-CoV-2/imunologia , Fatores Sexuais , Vacinação/estatística & dados numéricos
2.
Eur Rev Med Pharmacol Sci ; 25(23): 7218-7222, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34919220

RESUMO

OBJECTIVE: Anti-COVID-19 vaccines were mainly associated with non-serious adverse events (AEs), whose prevalence was reported to be up to 70% in healthcare workers (HCWs). This may lead to sick leave requests, but this impact has never been quantified. This study aimed to investigate the absence from work among HCWs following anti-COVID-19 vaccination. Its association with age and previous COVID-19 infection was also assessed. PATIENTS AND METHODS: This is a retrospective observational cross-sectional study on administrative data about sick leave requests after anti-COVID-19 vaccination. All the HCWs employed at the Niguarda Hospital (Milan, Italy) who received the vaccine from December 27, 2020 to February 28, 2021 were included. RESULTS: In total, 4,088 HCWs received the first dose of the vaccine and 4,043 completed the vaccination cycle. After the first injection, 1.6% of HCWs requested sick leave, while after the second injection, the number of requests significantly increased (+6.1%, p<0.001). A significant increase in sick leave was detected for those who have had SARS-CoV-2 infection after the first injection (+2.3%, p<0.001). After the second dose, a significant increase in sick leave was observed in the 20-30-year-old group compared to >30 years (+3.6%, p=0.017), if HCWs without a history of SARS-CoV-2 infection were considered. CONCLUSIONS: The requests for sick leave among HCWs following the anti-COVID-19 vaccine were limited and higher after the second injection. This may help the management of the human resources when the large-scale administration of the anti-COVID-19 vaccines will involve other categories of workers.


Assuntos
Vacina BNT162/administração & dosagem , COVID-19/prevenção & controle , Pessoal de Saúde/estatística & dados numéricos , Licença Médica/estatística & dados numéricos , Adulto , Fatores Etários , Vacina BNT162/efeitos adversos , Estudos Transversais , Feminino , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Adulto Jovem
3.
G Ital Med Lav Ergon ; 29(3 Suppl): 298-300, 2007.
Artigo em Italiano | MEDLINE | ID: mdl-18409694

RESUMO

With the aim of reducing the number of occupational accidents and of judgements of limited work ability among the nurses having as work task the movement of not self-sufficient patients, the Legnano Hospital has defined a project of substitution of the traditional hospital beds with electrical beds. We describe the project of substitution of the beds and the positive results both on the health status of the workers using electrical beds and on the reduction of the falls occurred to the patients.


Assuntos
Leitos , Setor de Assistência à Saúde , Pessoal de Saúde , Hospitais , Dor Lombar/prevenção & controle , Doenças Profissionais/prevenção & controle , Desenho de Equipamento , Humanos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa